TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23176547
Drug: 30-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-week oral language intervention, delivered in three group sessions per week and daily sessions during transition to Reception class
Study: 20471545
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel and cisplatin
Study: 9167741
Drug: Cis-platinum (CDDP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-platinum (CDDP) 40 mg/m2 weekly with fractionated stereotactic radiotherapy (SRT) once or twice weekly
Study: 8396083
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day once-daily for three days (n = 30)
Study: 3543784
Drug: Anterior subTenon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior subTenon injections (subconjunctival)
Study: 3543784
Drug: Posterior subTenon
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior subTenon injections (retrobulbar)
Study: 24885384
Drug: Oral flucloxacillin
Normalized name: cloxacillin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flucloxacillin for 6 additional days
Study: 23279214
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy program (3 days/week)
Study: 23279214
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy program (2 days/week)
Study: 20223672
Drug: Thalidomide (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100mg twice per day)
Study: 30659892
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy)
Study: 8821521
Drug: Vaginal tablets
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal tablets (Gynoflor) containing 50 mg of Lactobacillus acidophilus and 0.03 mg estriol, administered 1-2 tablets daily for 6 days.
Study: 8821521
Drug: Vaginal tablets
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal tablets (Gynoflor)
Study: 1384919
Drug: Prazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.5 mg and then 1 mg twice daily for 4 days, then 2 mg twice daily for the remainder of the trial)
Study: 3929579
Drug: TTS-NTG 10
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-NTG 10 mg
Study: 3929579
Drug: TTS-NTG 20
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-NTG 20 mg
Study: 19423958
Drug: Deep inspiration-gated
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep inspiration-gated radiation therapy (n=33)
Study: 11560567
Drug: Methionine 15
Normalized name: methionine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine 15 g
Study: 24914630
Drug: 24 mL
Normalized name: ethanol 0.724 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mL of mepivacaine 1% (group volume II)
Study: 19050607
Drug: Saline instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline instillation (8 mL of saline before tracheal suctioning)
Study: 10451477
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil and fish oil supplement (40 g/d of olive oil and 16 g of fish oil for 3 months)
Study: 7561177
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg until bone marrow recovery or initiation of intravenous amphotericin B infusions
Study: 29514368
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 100 mg hydrocortisone (given 2 hours before and 8 hours after surgery)
Study: 29514368
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of 100 mg hydrocortisone (8 hours apart)
Study: 21301358
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii at 2×10^6 live cells daily for 4 weeks
Study: 15644655
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily
Study: 14979482
Drug: Piperacillin/tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4.5 g three times a day
Study: 9918416
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream (P)
Study: 2840013
Drug: Fluconazole 25
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 25 mg/day
Study: 12879543
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg/day
Study: 2840013
Drug: Fluconazole (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (in vitro, up to 10 micrograms/ml)
Study: 2840013
Drug: Ketoconazole (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (in vitro, 0.1 microgram/ml)
Study: 23739857
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) associated with full-mouth ultrasonic debridement
Study: 19573384
Drug: IST regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IST regimen II (cyclosporine A and intravenous immunoglobulin)
Study: 16637377
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 mL saline solution)
Study: 16637377
Drug: Oxitocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitocin (10 UI in 2 mL diluted in 18 mL saline solution)
Study: 9882081
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol after antacid (Maalox)
Study: 8032167
Drug: Ritanserin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (2.5 mg, 5 mg, and 10 mg o.d.)
Study: 4921703
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside and daunorubicin with L-asparaginase (N=10)
Study: 21467560
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine (TAP group)
Study: 19538204
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment unchanged (58 control patients)
Study: 16776753
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily for 16 weeks
Study: 16776753
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Moxonidine and Metformin)
Study: 10752919
Drug: Salmeterol powder
Normalized name: salmeterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol powder 50 microg twice daily via Diskus
Study: 10752919
Drug: Salmeterol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol aerosol 42 microg twice daily via MDI
Study: 4029242
Drug: Oral prajmaline
Normalized name: prajmaline
DrugBank: Prajmaline (DB13555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prajmaline bitartrate
Study: 21737654
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection
Study: 21737654
Drug: Overall costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall costs of percutaneous ethanol injection
Study: 3046816
Drug: Caffeine, 300
Normalized name: Acetaminophen/Butalbital/Caffeine, 300 mg-50 mg-40 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine, 300 mg
Study: 3046816
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg
Study: 3046816
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg with placebo pretreatment
Study: 29370992
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (3 mg/kg every 2 weeks)
Study: 25357214
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (LHL group)
Study: 18721166
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice per day)
Study: 7910732
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy followed by in vivo exposure
Study: 3901674
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy alone
Study: 1709338
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion
Study: 19277420
Drug: Desmoteplase (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase (higher doses)
Study: 19277420
Drug: Alteplase 100
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 100 mg
Study: 15012646
Drug: Both immediate
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both immediate and delayed PLA injections
Study: 11376522
Drug: Evidence-Based Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-Based Medicine
Study: 24892221
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (6 times/week)
Study: 22364561
Drug: Home-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based modified constraint-induced movement therapy plus trunk restraints (3 hours/day, 5 days/week for 2 weeks)
Study: 22364561
Drug: Home-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based modified constraint-induced movement therapy (3 hours/day, 5 days/week for 2 weeks)
Study: 22364561
Drug: Home-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based modified constraint-induced movement therapy plus trunk restraints
Study: 22364561
Drug: Home-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based modified constraint-induced movement therapy
Study: 16098314
Drug: Anticoagulant and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant and/or antiplatelet treatment
Study: 12393567
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (Cy)
Study: 7551845
Drug: Piperacillin/tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (4.5 g intravenously 20 min before TPB)
Study: 1433582
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (151 children)
Study: 15826234
Drug: CVC nonwords
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC nonwords (e.g., pof)
Study: 15826234
Drug: CCVC frame
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCVC frame (e.g., grof)
Study: 15826234
Drug: CVCC frame
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVCC frame (e.g., goft)
Study: 8036288
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled by Turbuhaler (5 doses = 2.5 mg, t.i.d. for 2 weeks)
Study: 21511002
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of bromazepam
Study: 18312043
Drug: Start-taper switch
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start-taper switch (STS)
Study: 17002053
Drug: Artificial pneumoperitoneum
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial pneumoperitoneum (PP) with chemotherapy
Study: 20462054
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Control)
Study: 10919343
Drug: Biaxin 500
Normalized name: Biaxin 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biaxin 500 mg (reference formulation)
Study: 17493510
Drug: Oral Rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Rehydration Solution (ORS)
Study: 1603294
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant treatment (Imipramine)
Study: 28858981
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment not specified)
Study: 22613740
Drug: Lower body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower body negative pressure treatments (LBNP, -15 and -35 mmHg)
Study: 10047626
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of pravastatin
Study: 7744265
Drug: No AZT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No AZT therapy
Study: 7810285
Drug: AZT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT therapy
Study: 2116690
Drug: Cyclosporine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (10 mg/kg) daily during donor-specific transfusion (DST)
Study: 6451351
Drug: DepoProvera (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoProvera (all doses)
Study: 28780595
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray (Group V)
Study: 11772834
Drug: Lidocaine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (Group L)
Study: 26202595
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) plus veliparib 20 mg
Study: 26202595
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) plus veliparib 40 mg
Study: 23066973
Drug: PPA904 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA904 (active treatment)
Study: 19626470
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy with ABCB1 polymorphism
Study: 9715340
Drug: Individual problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual problem-solving treatment
Study: 9562516
Drug: Neutralizing anti-TNF-alpha
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing anti-TNF-alpha monoclonal antibodies
Study: 6347748
Drug: Quazepam 15
Normalized name: quazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 15 mg
Study: 6361006
Drug: Quazepam 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 30 mg
Study: 30470764
Drug: HIV positive
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV positive individuals not on antiretroviral treatment (ART)
Study: 20837852
Drug: Placebo (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (loading dose and maintenance every 3 weeks)
Study: 7491395
Drug: Lithium 600
Normalized name: lithium 600 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 600 mg loading dose
Study: 7035480
Drug: Oral prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylactic urea treatment (low doses)
Study: 31887743
Drug: MIV‐711, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV‐711, 100 mg daily
Study: 31887743
Drug: MIV‐711, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV‐711, 200 mg daily
Study: 29944510
Drug: Ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5% ophthalmic drops
Study: 25651245
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir disoproxil fumarate (TDF)
Study: 27922719
Drug: TDF in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF in combination with emtricitabine (FTC)
Study: 23136538
Drug: Multiple-dose parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Multiple-dose parecoxib
Study: 26250825
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + GPI
Study: 15457579
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no special treatment)
Study: 3338362
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy prior to the meal
Study: 3338362
Drug: No placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No placebo therapy prior to the meal
Study: 4948415
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed typhoid vaccine (3 tablets containing 100x10(9) killed Salmonella typhi)
Study: 30595283
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (group A)
Study: 30595283
Drug: Prasugrel 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 30 mg loading dose (group B)
Study: 8560677
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg/day)
Study: 22285316
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation 2.4 g/day (1,400 mg eicosapentaenoic acid + 1,000 mg docosahexaenoic acid)
Study: 7876610
Drug: One, two,
Approvals — FDA: no, EMA: no, PMDA: no
Description: One, two, or three doses of group A plus group C meningococcal polysaccharide‐CRM197 conjugate vaccine
Study: 7876610
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of conjugate vaccine at 6 months
Study: 7876610
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of conjugate vaccine
Study: 7876610
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of meningococcal A plus C polysaccharide vaccine
Study: 20346089
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg for 14 days)
Study: 16442481
Drug: Morphine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2.5 mg every 4 hours) with midazolam rescue doses (5 mg) for breakthrough dyspnea (Group Mo)
Study: 16442481
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg every 4 hours) with morphine rescue doses (2.5 mg) for breakthrough dyspnea (Group Mi)
Study: 8269574
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rates of 5.7 L.min‐1
Study: 24278989
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ranibizumab
Study: 10211014
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine alone
Study: 8422744
Drug: Levonorgestrel (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (250 mg) and Ethinyl Estradiol (50 micrograms)
Study: 29459121
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and manual therapy
Study: 29459121
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and manual therapy + IFC
Study: 29459121
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and manual therapy + placebo ultrasound
Study: 26884473
Drug: Long-acting (pegylated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting (pegylated) C-peptide 0.8 mg
Study: 26884473
Drug: Long-acting (pegylated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting (pegylated) C-peptide 2.4 mg
Study: 26884473
Drug: C-peptide therapy
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide therapy
Study: 10944641
Drug: Ondansetron 1
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 1 microg/kg twice per day
Study: 10944641
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 microg/kg twice per day
Study: 10944641
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 microg/kg twice per day
Study: 8998919
Drug: 23-valent vaccine
Normalized name: Pneumococcal 23-valent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent vaccine of capsular polysaccharides (Pneumovax 23)
Study: 1768820
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg)
Study: 26576424
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg) + Remifentanil (0.05 μg/kg)
Study: 23995984
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion strategy (Hb 10.8 g/dl)
Study: 11875365
Drug: Tolbutamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (500 mg)
Study: 6794584
Drug: Lysine acetyl
Normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetyl salicylate (LAS) 1.8 g
Study: 17397061
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (initial 10-week sham treatment)
Study: 19160722
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg o.d.
Study: 12830340
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg o.d.
Study: 8387912
Drug: Isabgol husk
Normalized name: Psyllium Husk
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isabgol husk (25 g) added to low-fibre diet
Study: 3111669
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg sodium fluoride (NaF) + 1 g calcium
Study: 3111669
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sodium fluoride (NaF) + calcium
Study: 19788472
Drug: Zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 5 mg
Study: 10326217
Drug: Weekly L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly L-asparaginase (l-Asp) during maintenance therapy as a late intensification
Study: 10326217
Drug: Standard maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maintenance therapy without additional L-asparaginase (l-Asp)